Corporate News
Receipt of deferred consideration
25 November 2022
Omega (AIM: ODX), the specialist medical diagnostics company focused on promoting a personalised and functional approach to health and nutrition, announces that it has now received the £4.0m of deferred consideration relating to the sale of the CD4 business.
Accordingly, as of close of business on 24 November 2022, Omega held cash balances of £6.5m.
The information communicated in this announcement is inside information for the purposes of Article 7 of EU Regulation 596/2014.
| Omega Diagnostics Group PLC | www.omegadx.com |
| Jag Grewal Chief Executive Officer | via Walbrook PR |
| Chris Lea, Chief Financial Officer | |
| finnCap Ltd | Tel: 020 7220 0500 |
| Geoff Nash/Edward Whiley (Corporate Finance) | |
| Alice Lane/ Harriet Ward (ECM) | |
| Walbrook PR Limited | Tel: 020 7933 8780 or [email protected] |
| Paul McManus | Mob: 07980 541 893 |
| Sam Allen | Mob: 07502 558 258 |
About Omega Diagnostics Group PLC
Omega (AIM: ODX) is a specialist medical diagnostics company focused on promoting a personalised and functional approach to health and nutrition. www.omegadx.com
Latest Share Price
Investor News
-
06 February 2025
Director/PDMR Shareholding -
30 January 2025
Director/PDMR Shareholding